| Literature DB >> 35419113 |
Oksana Mykolaivna Pavlovska1, Kateryna Mykolaivna Pavlovska2, Svitlana Mykolaivna Heryak3, Stefan Volodymyrovych Khmil4, Mariya Stefanivna Khmil4.
Abstract
The study involved clinical and laboratory examination of 54 women with vasomotor menopausal disorders divided into 3 subgroups depending on the duration of symptoms (not more than 12 months, about 3 years, from 5 to 7 years). The control group included 21 patients without vasomotor disorders during the menopausal period. Data from the general and obstetric-gynecological anamnesis and the results of objective and general clinical examinations were analyzed. To assess the state of intestinal microbiocenosis in patients, a bacteriological study of feces was used according to modern methods. In women with menopausal vasomotor disorders, chronic arterial hypertension, overweight, diabetes mellitus, chronic enterocolitis, and chronic pyelonephritis prevailed among somatic diseases. The study also revealed that these patients had a pronounced imbalance of the intensive microbiota, which was characterized by a significant decrease in the main representatives of the obligate microflora (Bifidobacterium, Lactobacillus) and an increase in the number of opportunistic strains (Klebsiella and Clostridiodes difficile). Considering modern concepts, a change in the microbial composition of the intestine may be one of the possible trigger factors for the occurrence of vasomotor menopausal disorders. Further research will clarify the influence of the microbiome on the formation of the pathological menopausal symptom complex and improve the preventive and therapeutic measures in this category of women. ©2022 JOURNAL of MEDICINE and LIFE.Entities:
Keywords: climacteric period; intestinal microbiota; menopausal vasomotor disorders
Mesh:
Year: 2022 PMID: 35419113 PMCID: PMC8999096 DOI: 10.25122/jml-2021-0106
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Concomitant somatic diseases of patients with climacteric vasomotor disorders (subgroup Ia, Ib, Ic) and women in the control group (group II).
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| |
|
| 8 | 40.0 | 3 | 16.7 | 6 | 37.5 | 2 | 9.5 |
|
| - | - | - | - | 1 | 6.3 | - | - |
|
| 5 | 25.0 | 4 | 22.2 | 3 | 18.8 | 3 | 14.3 |
|
| - | - | 1 | 5.6 | - | - | 2 | 9.5 |
|
| 6 | 30.0 | 5 | 27.8 | 2 | 12.5 | 4 | 19.0 |
|
| 2 | 10.0 | - | - | 1 | 6.3 | 1 | 4.8 |
|
| 1 | 5.0 | - | - | - | - | - | - |
|
| 6 | 30.0 | 6 | 33.3 | 5 | 31.3 | 3 | 14.3 |
|
| 3 | 16.0 | 2 | 11.1 | 2 | 12.5 | 1 | 4.8 |
|
| 5 | 25 | 4 | 22.2 | 5 | 31.3 | 1 | 4.8 |
|
| 1 | 5.0 | - | - | 4 | 25.0 | 1 | 4.8 |
|
| - | - | - | - | 2 | 12.5 | - | - |
|
| 4 | 20 | 3 | 16.7 | 4 | 25 | 5 | 23.8 |
The content of intestinal microorganisms in 1 g of feces in the patients with climacteric vasomotor disorders (subgroup Ia, Ib, Ic) and women in the control group (group II).
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
|
| 29.71±6.78 | 30.55±4.84 | 10.95±2.34 | 49.74±6.28 |
|
| 8.54±1.81 | 7.86±1.55 | 4.56±0.71 | 21.23±5.32 |
|
| 25.22±5.62 | 27.48±6.90 | 19.70±3.56 | 28.17±7.85 |
|
| 0.64±0.13 | 0.35±0.12 | 0.23±0.18 | 0.45±0.10 |
|
| 37.24±7.64 | 39.01±6.78 | 29.50±7.17 | 48.19±8.32 |
| Escherichia coli with normal enzymatic activity, (×106) | 15.21±8.16 | 19.98±8.44 | 14.60±5.76 | 34.91±7.14 |
|
| 29.74±5.21 | 21.18±6.12 | 24.78±7.29 | 14.50±4.36 |
| Staphylococcus epidermidis, (×104) | 0.90±0.22 | 0.76±0.10 | 1.25±0.28 | 0.98±0.18 |
|
| 1.63±0.39 | 2.05±0.54 | 2.18±0.48 | 0.57±0.09 |
| Enterobacter, (×103) | 2.54±0.53 | 2.76±0.48 | 3.10±0.60 | 2.81±1.08 |
|
| 1.73±0.42 | 1.47±0.24 | 2.01±0.68 | 1.51±0.38 |
| Clostridiodes difficile, (×105) | 0.49±0.07 | 0.82±0.11 | 1.34±0.40 | 0.19±0.04 |
|
| 1.08±0.19 | 0.80±0.09 | 1.27±0.27 | 0.91±0.22 |
| Candida albicans, (×104) | 0.53±0.17 | 0.68±0.13 | 0.87±0.22 | 0.46±0.10 |